Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09XUI
|
|||
| Drug Name |
1,5-diphenylpyrrolidin-2-one derivative 2
|
|||
| Synonyms |
PMID26161824-Compound-115
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Company |
ELI LILLY AND COMPANY SCHAUS, John, Mehner
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H22F6N4O2
|
|||
| Canonical SMILES |
CC(C)(C1=NC(=NC=C1)C(F)(F)F)NC2CC(N(C2=O)C3=CC=C(C=C3)OC(F)(F)F)C4=CC=CC=C4
|
|||
| InChI |
1S/C25H22F6N4O2/c1-23(2,20-12-13-32-22(33-20)24(26,27)28)34-18-14-19(15-6-4-3-5-7-15)35(21(18)36)16-8-10-17(11-9-16)37-25(29,30)31/h3-13,18-19,34H,14H2,1-2H3/t18-,19-/m1/s1
|
|||
| InChIKey |
RZNGNBDYOQOCCY-RTBURBONSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.